[Various induction therapies in older patients with acute myeloid leukemias].
Due to unmanageable complications the results of high-dose chemotherapy for remission induction were significantly worse in a group of elderly patients with AML than for younger ones (greater than vs. less than 50 years: CRR 44% vs. 78%, p = less than 0.005). Hence, different induction schedules were studied for older patients with AML. A high response rate to low-dose cytosine-arabinoside (LD-CAR) was observed in myeloblastic and promyelocytic leukaemias, but the complete remission rate was low. Induction treatment with VP 16-213, aclacinomycin, cytosine-arabinoside and thioguanine resulted in a high complete remission rate (69%). Toxic side effects cannot be excluded in individual cases. These results justify prospective studies to evaluate the significance of the efficacy of these induction schedules.
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000616:Aminoglutethimide / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D003561:Cytarabine / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007937:Leukapheresis; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use
D009279:Naphthacenes; C011157:aclacinomycins; D003561:Cytarabine; D013629:Tamoxifen; D000616:Aminoglutethimide; D005047:Etoposide; D015250:Aclarubicin; D003613:Danazol
Unterschiedliche Induktionstherapien bei älteren Patienten mit akuter myeloischer Leukämie.